Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Revvity, Inc. has filed a WARN notice indicating that it will lay off 29 employees in Boston, Massachusetts. This decision reflects the company's ongoing adjustments in response to current market conditions. The layoffs are part of a broader trend affecting various sectors, but specific reasons for Revvity's cuts were not detailed in the notice. The affected employees will be notified as part of the legal requirements associated with the WARN filing.
Revvity, Inc. has announced an increase in layoffs following the closure of its second site in Massachusetts. The company is laying off approximately 150 employees as part of its operational consolidation efforts. This decision comes as Revvity seeks to streamline its operations and reduce costs amid challenging market conditions. The layoffs are effective immediately, impacting various roles within the company. Revvity's actions reflect a broader trend in the tech industry, where companies are adjusting their workforce in response to economic pressures.
Revvity, Inc., a biomanufacturer based in Massachusetts, has announced plans to close its Boston facility, resulting in the layoff of dozens of employees. While the exact number of affected employees is not specified, reports indicate that approximately 36 positions will be eliminated as part of this closure. The decision reflects the company's ongoing restructuring efforts and aims to streamline operations. The layoffs are part of a broader trend in the industry, but specific details regarding the timeline for these layoffs have not been disclosed.
No one has shared a story from Revvity, Inc. yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.